Michael Metzger Net Worth

The estimated Net Worth of Michael A Metzger is at least $3.26 Million dollars as of 6 February 2023. Mr. Metzger owns over 5,959 units of Syndax Pharmaceuticals Inc stock worth over $432,682 and over the last 8 years he sold SNDX stock worth over $130,988. In addition, he makes $2,696,890 as President, Chief Operating Officer, and Director at Syndax Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Metzger SNDX stock SEC Form 4 insiders trading

Michael has made over 18 trades of the Syndax Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,959 units of SNDX stock worth $38,018 on 6 February 2023.

The largest trade he's ever made was exercising 100,000 units of Syndax Pharmaceuticals Inc stock on 4 November 2020 worth over $720,000. On average, Michael trades about 20,024 units every 49 days since 2017. As of 6 February 2023 he still owns at least 23,618 units of Syndax Pharmaceuticals Inc stock.

You can see the complete history of Mr. Metzger stock trades at the bottom of the page.

Michael Metzger biography

Michael A. Metzger serves as President, Chief Operating Officer, Director of the Company. Mr. Metzger has served as our President and Chief Operating Officer since May 2015. Prior to joining us, Mr. Metzger was President and COO from December 2013 to October 2014 and President and Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded biotechnology company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., a venture capital firm. Mr. Metzger currently serves on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company and Tarveda Therapeutics. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.

What is the salary of Michael Metzger?

As the President, Chief Operating Officer, and Director of Syndax Pharmaceuticals Inc, the total compensation of Michael Metzger at Syndax Pharmaceuticals Inc is $2,696,890. There are no executives at Syndax Pharmaceuticals Inc getting paid more.

How old is Michael Metzger?

Michael Metzger is 49, he's been the President, Chief Operating Officer, and Director of Syndax Pharmaceuticals Inc since 2019. There are 12 older and 3 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.

What's Michael Metzger's mailing address?

Michael's mailing address filed with the SEC is C/O SYNDAX PHARMACEUTICALS, INC., 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451.

Insiders trading at Syndax Pharmaceuticals Inc

Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin, and Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.

What does Syndax Pharmaceuticals Inc do?

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.

Complete history of Mr. Metzger stock trades at CTI BioPharma Corp and Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc executives and stock owners

Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Michael Metzger,
  President, Chief Operating Officer, Director
• Briggs Morrison,
  Chief Executive Officer, Director
• Dr. Briggs W. Morrison M.D.,
  CEO & Director
• Michael A. Metzger M.B.A.,
  Pres, COO & Director
• Michael Meyers,
  Senior Vice President, Chief Medical Officer
• Dennis Podlesak,
  Independent Chairman of the Board
• Pierre Legault,
  Independent Director
• Keith Katkin,
  Independent Director
• William Meury,
  Independent Director
• Fabrice Egros,
  Independent Director
• Jennifer Jarrett,
  Independent Director
• Peter Ordentlich,
  Chief Scientific Officer
• Luke Albrecht,
  Senior Vice President, General Counsel, Secretary
• Daphne Karydas,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Dr. Edward A. Sausville M.D., Ph.D.,
  Advisor
• Dr. Michael L. Meyers M.D., Ph.D.,
  Chief Medical Officer & Sr. VP
• Luke J. Albrecht,
  Sr. VP, Gen. Counsel & Sec.
• Alexander Nolte,
  Interim Principal Financial Officer, VP & Chief Accounting Officer
• Dr. Michael Downes Ph.D.,
  Co-Founder
• Dr. Ronald M. Evans Ph.D.,
  Co-Founder, Advisor and Chair of Scientific Advisory Board
• Dr. Richard A. Heyman Ph.D.,
  Co-Founder
• Dr. Peter Ordentlich B.Sc., Ph.D.,
  Co-Founder & Chief Scientific Officer
• Martin H. Jr. Huber,
  
• Neil Gallagher,
  President, Head of R&D
• Luke Evnin,
  Director
• Henry Chen,
  
• Partners L P/Ilbiotechnolog...,
  
• Steve M Sabus,
  Chief Commercial Officer
• Ivor Royston,
  Director
• Viii Associates, L.P.Blair ...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Partners Vi, L.P.Blair Jame...,
  
• George W. Jr. Sledge,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Kim P. Kamdar,
  Director
• Richard P Shea,
  Chief Financial Officer
• Alexander Nolte,
  Chief Accounting Officer
• Catherine Madigan,
  Chief Medical Officer
• Keith A. Goldan,
  Chief Financial Officer